Literature DB >> 10449611

Up-regulation of Lewis enzyme (Fuc-TIII) and plasma-type alpha1,3fucosyltransferase (Fuc-TVI) expression determines the augmented expression of sialyl Lewis x antigen in non-small cell lung cancer.

A Togayachi1, T Kudo, Y Ikehara, H Iwasaki, S Nishihara, T Andoh, M Higashiyama, K Kodama, S Nakamori, H Narimatsu.   

Abstract

Sialyl Lewis a and x antigens are well-known tumor-associated antigens expressed in many cancer tissues. The expression of the genes encoding 5 alpha1,3fucosyltransferases, which are able to synthesize the sialyl Lewis antigens, was examined in normal and cancerous lung tissues of patients with non-small cell lung carcinoma. In all 20 cases examined, the transcripts only for the Lewis gene, encoding the Lewis enzyme (alpha1,3/4fucosyltransferase, Fuc-TIII), were abundantly expressed in lung tissue, and interestingly they were markedly up-regulated in the lung cancer tissues of all 20 cases in comparison with normal lung tissues. Myeloid-type alpha1,3fucosyltransferase (Fuc-TIV) was expressed at an intermediate level but was not up-regulated in lung cancer tissues. The transcripts for plasma-type alpha1,3fucosyltransferase (Fuc-TVI) gene were detected at a very low level but were apparently up-regulated in cancer tissues. Fuc-TVI was found to exhibit stronger relative activity for sialyl Lewis x synthesis (almost 6. 4-fold that of Fuc-TIII). The amount of sialyl Lewis x antigen on mucins in the lung cancer tissues was found to be determined by both enzymes, the Lewis enzyme (Fuc-TIII) and Fuc-TVI. However, the amount of the sialyl Lewis a antigens was not determined by any of the alpha1,3-fucosyltransferases, although the expression of sialyl Lewis a antigens definitely required the Lewis enzyme. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10449611     DOI: 10.1002/(sici)1097-0215(19990924)83:1<70::aid-ijc14>3.0.co;2-k

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

Review 1.  Glycosylation alterations in lung and brain cancer.

Authors:  Hassan Lemjabbar-Alaoui; Andrew McKinney; Yi-Wei Yang; Vy M Tran; Joanna J Phillips
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

2.  Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin.

Authors:  Steven R Barthel; Jacyln D Gavino; Georg K Wiese; Jennifer M Jaynes; Javed Siddiqui; Charles J Dimitroff
Journal:  Glycobiology       Date:  2008-07-22       Impact factor: 4.313

Review 3.  Protein glycosylation in cancer.

Authors:  Sean R Stowell; Tongzhong Ju; Richard D Cummings
Journal:  Annu Rev Pathol       Date:  2015       Impact factor: 23.472

4.  Fucosylation and gastrointestinal cancer.

Authors:  Kenta Moriwaki; Eiji Miyoshi
Journal:  World J Hepatol       Date:  2010-04-27

5.  Metabolic inhibition of sialyl-Lewis X biosynthesis by 5-thiofucose remodels the cell surface and impairs selectin-mediated cell adhesion.

Authors:  Wesley F Zandberg; Jayakanthan Kumarasamy; B Mario Pinto; David J Vocadlo
Journal:  J Biol Chem       Date:  2012-09-27       Impact factor: 5.157

6.  Neutrophil interactions with sialyl Lewis X on human nonsmall cell lung carcinoma cells regulate invasive behavior.

Authors:  Catherine A St Hill; Katherine Krieser; Mariya Farooqui
Journal:  Cancer       Date:  2011-03-22       Impact factor: 6.860

7.  Carcinoembryonic antigen is a sialyl Lewis x/a carrier and an E‑selectin ligand in non‑small cell lung cancer.

Authors:  Inês Gomes Ferreira; Mylène Carrascal; A Gonçalo Mineiro; António Bugalho; Paula Borralho; Zélia Silva; Fabio Dall'olio; Paula A Videira
Journal:  Int J Oncol       Date:  2019-09-26       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.